A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
| Status: | Archived |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | May 2009 |
| End Date: | December 2011 |
A Phase I Study of Dasatinib With Concurrent Chemoradiation for Stage III NSCLC Principal Investigator: Howard Safran, MD.
The purpose of this study is to evaluate if a maximum dose of 100 mg of dasatinib with
concurrent chemoradiation can be tolerated in patients with chemotherapy naive stage III
NSCLC in separate cohorts of locally advanced and potentially resectable disease.
Describe the safety of maintenance dasatinib, 100 mg/day for 2 years, in patients with stage
III NSCLC.
For patients with potentially resectable disease, to assess the pathologic complete response
following neoadjuvant dasatinib, paclitaxel, carboplatin and 50.4 Gy concurrent radiation.
For patients with locally unresectable disease, to obtain radiographic response data
following dasatinib, paclitaxel, carboplatin and 64.8 Gy radiation.
We found this trial at
1
site
Click here to add this to my saved trials
